Whole-genome sequencing of Plasmodium falciparum from hundreds of infected people in Uganda has identified a rapidly spreading cluster of polymorphisms associated with decreased susceptibility to antimalarial drugs, according to findings published in Nature Medicine. The study focuses on new mutations linked to reduced performance of therapies used widely in sub-Saharan Africa. Researchers sequenced parasite genomes to pinpoint genetic determinants underlying a decline in drug susceptibility. The report includes reference to artemether-lumefantrine (AL) as the primary uncomplicated malaria treatment in Uganda and highlights broader concerns that parasite changes could undermine control efforts and increase deaths. Jeffrey Bailey, MD, PhD at Brown University described the spread as concerning, noting that rapid dissemination suggests the variants support parasite survival. Karamoko Niaré, PhD, also in Bailey’s lab at the time, said sequencing the entire genome was intended to clarify the exact genetic basis for reduced drug susceptibility. The study’s practical implication for malaria programs is renewed focus on surveillance systems that track both known resistance mutations and real-world treatment performance over time, using genetic markers to flag shifts earlier.